Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crinetics Pharmaceuticals (FRA:6Z4) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Crinetics Pharmaceuticals Forward PE Ratio Related Terms
Crinetics Pharmaceuticals Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals Forward PE Ratio Chart
Crinetics Pharmaceuticals Annual Data
Trend
Forward PE Ratio
Crinetics Pharmaceuticals Quarterly Data
Forward PE Ratio
FRA:6Z4 vs SYRE, PTGX, PRAX: Forward PE Ratio Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Forward PE Ratio falls into.
Crinetics Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Crinetics Pharmaceuticals (FRA:6Z4) has a Forward PE Ratio of 0.00 as of Aug. 19, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Crinetics Pharmaceuticals and its competitors. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #999999 out of 357 companies in the Biotechnology industry.
Is Crinetics Pharmaceuticals' Forward PE Ratio too high?
Crinetics Pharmaceuticals' current Forward PE Ratio is 0.00. Based on the distribution chart, Crinetics Pharmaceuticals ranks #999999 out of 357 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Forward PE Ratio compare to SYRE and PTGX?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #999999 out of 357 companies for Forward PE Ratio. This places Crinetics Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 22.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.88, based on 357 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €816.19, compared to a current price of €71.30 — trading 91.3% below its estimated fair value. The current Forward PE Ratio is 0.00. Crinetics Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Forward PE Ratio is 0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of €71.30 is trading 91.3% below its estimated GF Value™ of €816.19.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:6Z4:
Forward PE Ratio: 0.00
GF Value™: €816.19 vs. price of €71.30 (91.3% below fair value)
No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
35GF Score
Get the complete analysis for FRA:6Z4
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Z4 has been successfully added to your 
